ストックスクリーナーアプリを入手
205.26
0.14%
-0.29
前日終値:
$205.55
開ける：
$206.99
24時間の取引高:
1.17M
Relative Volume:
0.46
時価総額：
$43.99B
収益：
$742.00K
当期純損益:
$-1.37B
株価収益率:
-29.02
EPS:
-7.0731
ネットキャッシュフロー:
$-1.07B
1週間 パフォーマンス:
+4.03%
1か月 パフォーマンス:
+9.84%
6か月 パフォーマンス:
+110.89%
1年 パフォーマンス:
+482.13%
1日の値動き範囲:
$203.75
$208.49
1週間の範囲:
$195.42
$208.76
52週間の値動き範囲:
$34.88
$208.76
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
650-481-6801
住所
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
205.26 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
525.73 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.99 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.00 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
359.05 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-02-27 | 再開されました | UBS | Buy |
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-11-03 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-09-12 | 再開されました | Raymond James | Strong Buy |
| 2025-09-05 | 開始されました | Truist | Buy |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-08-15 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2024-07-16 | 繰り返されました | Needham | Buy |
| 2024-07-12 | 開始されました | Barclays | Overweight |
| 2024-07-08 | 開始されました | Jefferies | Buy |
| 2024-04-12 | 繰り返されました | Needham | Buy |
| 2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-04 | 開始されました | Wedbush | Outperform |
| 2023-11-16 | 開始されました | Raymond James | Outperform |
| 2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-10-21 | 開始されました | Oppenheimer | Outperform |
| 2022-05-20 | 開始されました | BofA Securities | Neutral |
| 2022-03-01 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
| 2021-05-18 | 開始されました | Goldman | Buy |
| 2020-05-21 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-09 | 開始されました | Cowen | Outperform |
| 2020-03-09 | 開始されました | Guggenheim | Buy |
| 2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - AOL.com
(RVMD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revolution and BeOne Meds enter research pact - thepharmaletter.com
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest. - pluang.com
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - finance.yahoo.com
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value - simplywall.st
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD - marketbeat.com
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD - marketbeat.com
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand - finance.yahoo.com
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) DealHas The Bull Case Changed? - finance.yahoo.com
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach - finance.yahoo.com
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach? - finance.yahoo.com
BeOne and Revolution Medicines partner for oncology therapies - Pharmaceutical Business review -
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies - Pharmaceutical Executive
REVOLUTION MEDICINES, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $231 FROM $210 - Bitget
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighShould You Buy? - marketbeat.com
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD - marketbeat.com
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus - simplywall.st
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia - AllSci
Revolution Medicines stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies - Oncodaily
Revolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations - Bitget
BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration - tradingview.com
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - Business Wire
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Powerhouse with a Bold Vision for Cancer Treatment - DirectorsTalk Interviews
REVOLUTION MEDICINES, INC. : JP MORGAN RAISES TARGET PRICE TO $227 FROM $205 - Bitget
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next - webull.com
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD - marketbeat.com
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $291 - moomoo.com
Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD - marketbeat.com
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years - Sahm
'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug - The Business Journals
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $201 to $240 - Moomoo
High Risk, High Reward: Inside The Revolution Medicines Bull Case (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines nears commercial launch wi... - Pluang
Oppenheimer Adjusts PT on Revolution Medicines to $230 From $195, Maintains Outperform Rating - Moomoo
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View - tradingview.com
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside - tradingview.com
RBC Adjusts PT on Revolution Medicines to $203 From $182, Maintains Outperform Speculative Risk Rating - marketscreener.com
Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00 - MarketBeat
Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD - marketbeat.com
Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highligh - GuruFocus
Revolution Medicines Q2 Earnings Call Highlights - marketbeat.com
Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results - MarketBeat
Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses - Endpoints News
Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026 - Investing.com
Revolution Medicines, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Revolution Medicines falls on second quarter earnings miss By Investing.com - Investing.com Nigeria
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings - 24/7 Wall St.
Revolution Medicines, Inc. Q2 2026: Net loss $(644.4M), EPS $(3.06) — 10-Q Summary - tradingview.com
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
0.06%
1.30%
大文字化:
|
ボリューム (24 時間):